IL106665A - Powder compositions for inhalation and process for their preparation - Google Patents

Powder compositions for inhalation and process for their preparation

Info

Publication number: IL106665A
Authority: IL; Israel
Prior art keywords: weight; composition according; carrier; microns; drug
Prior art date: 1992-08-14

Application number

IL106665A

Other languages

English (en)

Other versions

IL106665A0 (en

Original Assignee

Rhone Poulenc Rorer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-14

Filing date

1993-08-12

Publication date

1998-02-22

1993-08-12 Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd

1993-12-08 Publication of IL106665A0 publication Critical patent/IL106665A0/xx

1998-02-22 Publication of IL106665A publication Critical patent/IL106665A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 102
239000000843 powder Substances 0.000 title claims abstract description 38
238000000034 method Methods 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 7
239000003814 drug Substances 0.000 claims abstract description 40
229940079593 drug Drugs 0.000 claims abstract description 33
239000002216 antistatic agent Substances 0.000 claims abstract description 24
239000002245 particle Substances 0.000 claims description 31
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
150000001875 compounds Chemical class 0.000 claims description 13
238000009826 distribution Methods 0.000 claims description 13
239000008101 lactose Substances 0.000 claims description 13
-1 sorbitan fatty acid ester Chemical class 0.000 claims description 13
238000002156 mixing Methods 0.000 claims description 9
239000000654 additive Substances 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
239000007787 solid Substances 0.000 claims description 8
230000000996 additive effect Effects 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 7
229920001184 polypeptide Polymers 0.000 claims description 6
102000004196 processed proteins & peptides Human genes 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
125000000623 heterocyclic group Chemical group 0.000 claims description 5
235000000346 sugar Nutrition 0.000 claims description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
150000003936 benzamides Chemical class 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
229920001214 Polysorbate 60 Polymers 0.000 claims description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
239000008121 dextrose Substances 0.000 claims description 2
229940112141 dry powder inhaler Drugs 0.000 claims description 2
229960001022 fenoterol Drugs 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
102000055006 Calcitonin Human genes 0.000 claims 1
108060001064 Calcitonin Proteins 0.000 claims 1
IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 claims 1
239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
239000004147 Sorbitan trioleate Substances 0.000 claims 1
229950000210 beclometasone dipropionate Drugs 0.000 claims 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
229960004015 calcitonin Drugs 0.000 claims 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
235000019337 sorbitan trioleate Nutrition 0.000 claims 1
229960000391 sorbitan trioleate Drugs 0.000 claims 1
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 1
239000002775 capsule Substances 0.000 description 16
238000011049 filling Methods 0.000 description 14
210000004072 lung Anatomy 0.000 description 7
238000009472 formulation Methods 0.000 description 5
230000000694 effects Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
229910021653 sulphate ion Inorganic materials 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
238000005429 filling process Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000003068 static effect Effects 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000012546 transfer Methods 0.000 description 2
206010011224 Cough Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
238000012369 In process control Methods 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010038731 Respiratory tract irritation Diseases 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000005239 aroylamino group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000005611 electricity Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010965 in-process control Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000000420 mucociliary effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008249 pharmaceutical aerosol Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000012545 processing Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015096 spirit Nutrition 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000004753 textile Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Otolaryngology (AREA)
Life Sciences & Earth Sciences (AREA)
Pulmonology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL106665A 1992-08-14 1993-08-12 Powder compositions for inhalation and process for their preparation IL106665A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9217312A GB2269992A (en)	1992-08-14	1992-08-14	Powder inhalation formulations

Publications (2)

Publication Number	Publication Date
IL106665A0 IL106665A0 (en)	1993-12-08
IL106665A true IL106665A (en)	1998-02-22

Family

ID=10720370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106665A IL106665A (en)	1992-08-14	1993-08-12	Powder compositions for inhalation and process for their preparation

Country Status (16)

Country	Link
US (1)	US5908639A (de)
EP (1)	EP0654991B1 (de)
JP (1)	JP3787573B2 (de)
AT (1)	ATE154237T1 (de)
AU (1)	AU678379B2 (de)
CA (1)	CA2142126C (de)
DE (1)	DE69311556T2 (de)
DK (1)	DK0654991T3 (de)
ES (1)	ES2106362T3 (de)
GB (1)	GB2269992A (de)
GR (1)	GR3024468T3 (de)
IL (1)	IL106665A (de)
MX (1)	MX9304975A (de)
NZ (1)	NZ254945A (de)
WO (1)	WO1994004133A1 (de)
ZA (1)	ZA935943B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9322014D0 (en)	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) *	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US6017963A (en) *	1995-11-14	2000-01-25	Euro-Celtique, S.A.	Formulation for intranasal administration
US20020052310A1 (en)	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
US5874064A (en) *	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5871010A (en) *	1996-06-10	1999-02-16	Sarnoff Corporation	Inhaler apparatus with modified surfaces for enhanced release of dry powders
FR2756739B1 (fr) *	1996-12-05	2000-04-28	Astra Ab	Nouvelle formulation de budesonide
SE9700133D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
EP1006794B1 (de)	1997-03-12	2007-11-28	Robert W. Esmond	Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US6565885B1 (en) *	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6956021B1 (en)	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US6191154B1 (en)	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
JP4691298B2 (ja) *	1999-10-12	2011-06-01	科研製薬株式会社	粉末吸入用製剤及びその製造方法
DE60025019T2 (de)	1999-10-29	2006-08-24	Nektar Therapeutics, San Carlos	Trockenpulverzusammensetzungen mit verbesserter dispersivität
AU2001230533A1 (en) *	2000-02-04	2001-08-14	Kissei Pharmaceutical Co. Ltd.	Powdered preparation for inhalation and powder inhalant containing the same packed
US7089934B2 (en)	2000-02-28	2006-08-15	Vectura Limited	Delivery of oral drugs
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1296651E (pt)	2000-06-27	2008-02-12	Vectura Ltd	Método para fazer partículas para serem usadas numa composição farmacêutica
CA2413692C (en) *	2000-06-27	2011-10-18	Vectura Limited	Method of making particles for use in a pharmaceutical composition
EP2168571B1 (de) *	2000-11-30	2018-08-22	Vectura Limited	Inhalierbare Arzneizusammensetzung
EP2283818B1 (de)	2000-11-30	2017-08-02	Vectura Limited	Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung
WO2002053190A2 (en)	2000-12-29	2002-07-11	Advanced Inhalation Research, Inc.	Particles for inhalation having sustained release properties
WO2003020197A1 (en)	2001-09-05	2003-03-13	Vectura Limited	Improvements in or relating to the delivery of oral drugs
CA2465675C (en)	2001-11-20	2008-06-10	Advanced Inhalation Research, Inc.	Improved particulate compositions for pulmonary delivery
JP2005514393A (ja)	2001-12-19	2005-05-19	ネクターセラピューティクス	アミノグリコシドの肺への供給
WO2003074029A1 (en)	2002-03-07	2003-09-12	Vectura Limited	Fast melt multiparticulate formulations for oral delivery
US6923175B2 (en)	2002-03-20	2005-08-02	Mannkind Corporation	Inhalation apparatus
WO2004073729A1 (ja)	2003-02-21	2004-09-02	Translational Research Ltd.	薬物の経鼻投与用組成物
CA2519287A1 (en)	2003-03-27	2004-10-14	Bioactis Limited	Powder medicine applicator for nasal cavity
ITMI20040795A1 (it) *	2004-04-23	2004-07-23	Eratech S R L	Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
WO2006016530A1 (ja)	2004-08-10	2006-02-16	Translational Research, Ltd.	速効性でかつ高い吸収性を可能とする経鼻投与用組成物
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
KR20130066695A (ko)	2004-08-23	2013-06-20	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP1657278A1 (de)	2004-11-12	2006-05-17	SOLVAY (Société Anonyme)	Beschichtete Calciumcarbonat-Teilchen mit grosser spezifischer Oberfläche
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US20070172430A1 (en) *	2006-01-20	2007-07-26	Nastech Pharmaceutical Company Inc.	Dry powder compositions for rna influenza therapeutics
EP1986679B1 (de)	2006-02-22	2017-10-25	MannKind Corporation	Verfahren zur verbesserung der pharmazeutischen eigenschaften von mikropartikeln mit diketopiperazin und einem wirkstoff
CN101668544B (zh)	2006-12-26	2013-04-24	株式会社新日本科学	经鼻投用制剂
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
CN101827626B (zh)	2008-06-13	2015-03-18	曼金德公司	干粉吸入器和用于药物输送的系统
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
JP5936353B2 (ja) *	2008-07-18	2016-06-22	プロソニックスリミテッドＰｒｏｓｏｎｉｘＬｉｍｉｔｅｄ	フルチカゾン粒子の結晶化度を改善する方法
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
LT2400950T (lt)	2009-02-26	2019-08-26	Glaxo Group Limited	Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US9101539B2 (en)	2009-05-15	2015-08-11	Shin Nippon Biomedical Laboratories, Ltd.	Intranasal pharmaceutical compositions with improved pharmacokinetics
KR102584844B1 (ko)	2009-06-12	2023-10-04	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
GB2472327B (en)	2009-07-31	2013-03-13	Shin Nippon Biomedical Lab Ltd	Intranasal granisetron and nasal applicator
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
CN102985125A (zh)	2010-06-21	2013-03-20	曼金德公司	干粉药物输送系统和方法
SG194034A1 (en)	2011-04-01	2013-11-29	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
MX2014004983A (es)	2011-10-24	2014-09-22	Mannkid Corp	Metodos y composiciones para tratar dolor.
KR102264177B1 (ko)	2012-07-12	2021-06-11	맨카인드 코포레이션	건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
EP3587404B1 (de)	2013-03-15	2022-07-13	MannKind Corporation	Mikrokristalline diketopiperazinzusammensetzungen, verfahren zur herstellung und deren verwendung
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (de)	2013-08-05	2020-10-07	MannKind Corporation	Insufflationsvorrichtung
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US11744967B2 (en)	2017-09-26	2023-09-05	Shin Nippon Biomedical Laboratories, Ltd.	Intranasal delivery devices
TW202210072A (zh)	2020-05-26	2022-03-16	美商羅德科技公司	用於鼻內或吸入遞送之大麻素組合物及劑型
JP7606825B2 (ja) *	2020-06-15	2024-12-26	東和薬品株式会社	エソメプラゾール顆粒ならびにその製造方法および用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4581225A (en) *	1984-04-25	1986-04-08	Eli Lilly And Company	Sustained release intranasal formulation and method of use thereof
US4916230A (en) *	1984-07-02	1990-04-10	Merck & Co., Inc.	Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
ATE77947T1 (de) *	1987-04-09	1992-07-15	Fisons Plc	Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5039699A (en) *	1989-03-27	1991-08-13	Lederle (Japan), Ltd.	Anti-peptic ulcer agent
JPH05963A (ja) *	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
GB9020544D0 (en) *	1990-09-20	1990-10-31	Sandoz Ltd	Improvements in or relating to organic compounds
IE71647B1 (en) *	1991-01-28	1997-02-26	Rhone Poulenc Rorer Ltd	Benzamide derivatives

1992
- 1992-08-14 GB GB9217312A patent/GB2269992A/en not_active Withdrawn
1993
- 1993-08-12 IL IL106665A patent/IL106665A/en not_active IP Right Cessation
- 1993-08-13 EP EP93918018A patent/EP0654991B1/de not_active Expired - Lifetime
- 1993-08-13 AU AU47256/93A patent/AU678379B2/en not_active Expired
- 1993-08-13 CA CA002142126A patent/CA2142126C/en not_active Expired - Lifetime
- 1993-08-13 DK DK93918018.8T patent/DK0654991T3/da active
- 1993-08-13 ES ES93918018T patent/ES2106362T3/es not_active Expired - Lifetime
- 1993-08-13 JP JP50601794A patent/JP3787573B2/ja not_active Expired - Fee Related
- 1993-08-13 DE DE69311556T patent/DE69311556T2/de not_active Expired - Lifetime
- 1993-08-13 ZA ZA935943A patent/ZA935943B/xx unknown
- 1993-08-13 AT AT93918018T patent/ATE154237T1/de active
- 1993-08-13 NZ NZ254945A patent/NZ254945A/en not_active IP Right Cessation
- 1993-08-13 WO PCT/GB1993/001720 patent/WO1994004133A1/en not_active Ceased
- 1993-08-16 MX MX9304975A patent/MX9304975A/es unknown
1997
- 1997-03-19 US US08/821,702 patent/US5908639A/en not_active Expired - Lifetime
- 1997-08-14 GR GR970402106T patent/GR3024468T3/el unknown

Also Published As

Publication number	Publication date
CA2142126C (en)	2007-01-09
GB9217312D0 (en)	1992-09-30
DK0654991T3 (da)	1997-12-29
US5908639A (en)	1999-06-01
JPH08500109A (ja)	1996-01-09
CA2142126A1 (en)	1994-03-03
EP0654991B1 (de)	1997-06-11
IL106665A0 (en)	1993-12-08
ATE154237T1 (de)	1997-06-15
GR3024468T3 (en)	1997-11-28
WO1994004133A1 (en)	1994-03-03
JP3787573B2 (ja)	2006-06-21
ES2106362T3 (es)	1997-11-01
ZA935943B (en)	1994-06-09
GB2269992A (en)	1994-03-02
DE69311556T2 (de)	1997-12-04
NZ254945A (en)	1996-06-25
DE69311556D1 (de)	1997-07-17
MX9304975A (es)	1994-05-31
AU678379B2 (en)	1997-05-29
AU4725693A (en)	1994-03-15
EP0654991A1 (de)	1995-05-31

Legal Events

Date	Code	Title
1998-08-16	FF	Patent granted
1999-01-26	KB	Patent renewed
1999-12-31	KB	Patent renewed
2003-10-31	KB	Patent renewed
2007-10-31	KB	Patent renewed
2014-03-31	EXP	Patent expired

Publication	Publication Date	Title
EP0654991B1 (de)	1997-06-11	Inhalationspulver enthaltend antistatisches hilfsmittel
EP0731688B1 (de)	2003-03-05	Aerosole als darreichungsform mit cfc-freiem treibmittel
US6372246B1 (en)	2002-04-16	Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US20070253913A1 (en)	2007-11-01	Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
JP2007513152A (ja)	2007-05-24	耐湿性容器内のチオトロピウムから構成される医薬製品
AU2003218306B2 (en)	2006-09-14	Method for administration of growth hormone via pulmonary delivery
HUP0101608A2 (hu)	2002-03-28	Aeroszol formájú gyógyszerkészítmény és eljárás előállítására
NZ246047A (en)	1997-03-24	Powder for inhalation comprising a micronised active ingredient and an excipient which has particles of 20um or more and finer particles of 10 um or less
PL207377B1 (pl)	2010-12-31	Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie
ZA200601045B (en)	2007-04-25	Aerosol formulation for inhalation, containing an anticholinergic agent
US20060292083A1 (en)	2006-12-28	Inhalation compositions with high drug ratios
HK1200343A1 (en)	2015-08-07	An inhalable medicament comprising tiotropium
US20210154137A1 (en)	2021-05-27	Dry powder vancomycin compositions and associated methods
US20020155068A1 (en)	2002-10-24	Inhalatory compositions of formoterol
US20050287078A1 (en)	2005-12-29	Minimizing powder retention on surfaces
CA2499280A1 (en)	2004-03-04	Inhalation compositions with high drug ratios
EP2957553A1 (de)	2015-12-23	Pharmazeutische formulierungen von vilanterol
EP2957552B1 (de)	2020-01-22	Vilanterolformulierungen
CA2360649C (en)	2005-09-20	Method of preparing particles for agglomeration
JP2025526811A (ja)	2025-08-15	吸入可能なエピネフリン製剤
EP2957551B1 (de)	2020-01-15	Trockenpulverformulierungen mit vilanterol
GB1333767A (en)	1973-10-17	Pharmaceutical compositions for inhalation comprising n-isopropyl noratropinium methylate salts
EA003193B1 (ru)	2003-02-27	Микронизированные фармацевтические композиции
WO2014205030A1 (en)	2014-12-24	Pulmonary administration of rotigotine
US20050163725A1 (en)	2005-07-28	Method for administration of growth hormone via pulmonary delivery